NEW YORK, Oct. 30, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced the filing with the Securities and Exchange Commission (the “SEC”) of a shelf registration statement on Form S-3 with respect to its common stock and warrants to purchase common stock. After the registration statement is declared effective by the SEC, SIGA will have the flexibility to raise funds up to an aggregate of $100 million and issue registered common stock and warrants to purchase common stock, from time to time, in one or more separate offerings with the size, price and terms to be determined at the time of issuance. SIGA currently intends to use the net proceeds from any sale of securities for general corporate purposes, including development of its product candidates, the acquisition or in-license of technologies, products or businesses, working capital and capital expenditures. SIGA may set forth additional information on the use of proceeds from any sale of securities in a prospectus supplement relating to the specific primary offering.
